書籍詳細

●基礎編

P.15 掲載の参考文献

• 1) LeRoith D, Roberts CT Jr:The insulin-like growth factor system and cancer. Cancer Lett 195:127-137, 2003
  pubmed

• 2) Saukkonen T, Dunger DB:Diabetes. In:Insulin-Like Growth Factors, ed. by LeRoith D, Zumkeller W, Baxter R, Eurekah.com., 2003, pp.441-456

• 3) 島津章, 葛谷英嗣:治療薬としてのIGF-1. 内分泌・糖尿病科 15 (suppl 1):297-301, 2002

P.17 掲載の参考文献

• 1) Matsuzawa Y, Shimomura I, Nakamura T et al:Pathophysiology and pathogenesis of visceral fat obesity. Ann N Y Acad Sci 748:399-406, 1995
  pubmed

• 2) Okubo K, Hori N, Matoba R et al:Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat Genet 2:173-179, 1992
  pubmed

• 3) Maeda K, Okubo K, Shimomura I et al:Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235, 1997
  pubmed

• 4) Shimomura I, Funahashi T, Takahashi M et al:Enhanced expression of PAI-1 in visceral fat:Possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996
  pubmed

• 5) Spiegelman BM, Flier JS:Adipogenesis and obesity:rounding out the big picture. Cell 87:377-389, 1996
  pubmed

• 6) Friedman, JM, Halaas, JL:Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998
  pubmed

• 7) Matsuzawa Y, Funahashi T, Kihara S et al:Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

P.19 掲載の参考文献

• 1) Matsuzawa Y, Funahashi T, Kihara S et al:Adiponectin and Metabolic Syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 2) Nakamura T, Matsuzawa Y:Life-style related disease and adipocytes. Intern Med 41:68-70, 2002
  pubmed

• 3) Funahashi T, Nakamura T, Shimomura I et al:Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202-206, 1999
  pubmed

P.21 掲載の参考文献

• 1) Eizirik DL, Mandrup-Poulsen T:A choice of death the signal-transduction of immune-mediated beta-cell apoptosis Diabetologia 44:2115-2133, 2001
  pubmed

• 2) Hotamisligil GS:Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 24 (suppl 4):S23-S27, 2000

• 3) Satoh J, Yagihashi S, Toyota T:The possible role of tumor necrosis factor-α in diabetic polyneuropathy Exp Diabesity Res 4:65-71, 2003

P.23 掲載の参考文献

• 1) Friedman JM, Halaas JL:Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998
  pubmed

• 2) Spiegelman BM, Flier JS:Obesity and the regulation of energy balance. Cell 104:531-543, 2001
  pubmed

• 3) Steppan CM, Lazar MA:Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13:18-23, 2002
  pubmed

P.25 掲載の参考文献

• 1) Juntti-Berggren L, Larsson O, Rorsman P et al:Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. Science 261:86-90, 1993
  pubmed

• 2) Lorenzo A, Razzaboni B, Weir GC et al:Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature 368:756-760, 1994
  pubmed

• 3) Kaneto H, Fujii J, Seo HG et al:Apoptotic cell death triggered by nitric oxide in pancreatic β-cells. Diabetes 44:733-738, 1995

• 4) Kaneto H, Kajimoto Y, Miyagawa J et al:Beneficial effects of antioxidants in diabetes:possible protection of pancreatic β-cells against glucose toxicity Diabetes 48:2398-2406, 1999

P.27 掲載の参考文献

• 1) 三家登喜夫:アミリン. 日本臨牀 60 (増刊7:新時代の糖尿病学1):517-522, 2002

• 2) 坂頭節哉, 三家登喜夫:アミリン遺伝子 (IAPP 遺伝子) 異常. 日本臨牀 60 (増刊7:新時代の糖尿病学 1):653-658, 2002

• 3) 三家登喜夫:アミリン遺伝子異常. 糖尿病遺伝子診断ガイド (第2版), 日本糖尿病学会編, 文光堂, 2003, pp.58-61

P.29 掲載の参考文献

• 1) Neel JV:The "thrifty genotype" in 1998. Nutr Rev 57:S2-S9, 1999
  pubmed

• 2) Pritchard JK, Cox NJ:The allelic architecture of human disease genes:common disease-common variant... or not? Hum Mol Genet 11:2417-2423, 2002
  pubmed

• 3) Haga H, Yamada R, Ohnishi Y et al:Gene-based SNP discovery and part of the Japanese Millennium Genome Project:identification of 190, 562 genetic variations in the human genome single-nucleotide polymorphism. J Hum Genet 47:605-610, 2002
  pubmed

P.31 掲載の参考文献

• 1) 山内俊一:1, 5-アンヒドログルシトール (1,5AG). 日本臨牀 60(増刊8:新時代の糖尿病学2):410-414, 2002

P.33 掲載の参考文献

• 1) 吉村哲彦:NO (一酸化窒素)-宇宙から細胞まで-. 共立出版, 東京, 1998

• 2) 谷口直之:NO と IDDM. 臨床免疫 29:579-584, 1997

• 3) 西尾善彦:糖尿病合併症と酸化ストレス. 別冊・医学のあゆみ:酸化ストレスーフリーラジカル医学生物学の最前線, 吉川敏一編, 医歯薬出版, 東京, 2001, pp.270-273

• 4) Mandrup-Poulsen T:beta-cell apoptosis:stimuli and signaling. Diabetes 50 (suppl 1):S58-S63, 2001

• 5) McFarlane SI, Kumar A, Sowers JR:Mechanisms by which angiotensin-converting enzyme inhibitiors prevent diabetes and cardiovascular disease. Am J Cardiol 91:30H-37H, 2003

P.35 掲載の参考文献

• 1) Holst JJ:Gastric inhibitory polypeptide analogues:do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1? BioDrugs 16:175-181, 2002
  pubmed

• 2) Miyawaki K, Yamada Y, Yano H et al:Glucose intolerance caused by a defect in the entero-insular axis:a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847, 1999

• 3) Miyawaki K, Yamada Y, Ban N et al:Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742, 2002
  pubmed

P.37 掲載の参考文献

• 1) 南條輝志男, 三家登喜夫:インスリン異常症. Molecular Medicine 32 (臨時増刊号:遺伝子病マニュアル):2-3, 1995

• 2) Steiner DF, Tager HS, Chan SJ et al:Insulin gene mutations:Lessons learned from molecular biology. Diabetes Care 13:600-609, 1990
  pubmed

• 3) 小泉昭夫, 嘉陽毅, 長谷山俊之:秋田マウス. 分子糖尿病学の進歩 1999, 矢崎義雄監修, 金原出版, 東京, 1999, pp.187-194

• 4) OMIM (Online Mendelian Inheritance in Man) *176730 INSULIN:http://www.ncbi.nih.gov/Omim/

P.39 掲載の参考文献

• 1) Pessin JE, Saltiel AR:Signaling Pathways in insulin action:molecular targets of insulin resistance. J Clin Invest 106:165-169, 2000
  pubmed

• 2) 荒木栄一, 河島淳司, 水流添覚:細胞内インスリン情報伝達系とインスリン抵抗性. 臨床成人病 31:1071-1077, 2001

• 3) 西澤昭彦, 小川渉:インスリン抵抗性の分子機構- PI3-キナーゼとその下流のシグナルとインスリン抵抗性-. 最新医学 57:1768-1772, 2002
  Medical*Online

P.41 掲載の参考文献

• 1) Lee J, Pilch PF:The insulin receptor:structure, function, and signaling. Am J Physiol 266:C319-C334, 1994
  pubmed

• 2) Taylor SI:Lilly Lecture:molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41:1473-1490, 1992
  pubmed

• 3) Okamoto H, Accili D:In vivo mutagenesis of the insulin receptor. J Biol Chem 278:28359-28362, 2003
  pubmed

P.43 掲載の参考文献

• 1) Makino H, Taira M, Shimada F et al:Insulin receptor gene mutation:a molecular genetical and functional analysis. Cell Signal 4:351-363, 1992
  pubmed

• 2) Taylor SI, Arioglu E:Syndrome associated with insulin resistance and acanthosis nigricans. J Basic Clin Physiol Pharmacol 9:419-439, 1998
  pubmed

• 3) Mauvais-Jarvis F, Kulkarni RN, Kahn CR:Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clin Endocrinol 57:1-9, 2002
  pubmed

P.45 掲載の参考文献

• 1) Winder WW, Hardie DG:AMP-activated protein kinase, a metabolic master switch:possible roles in Type 2 diabetes. Am J Physiol 277:E1-E10, 1999
  pubmed

• 2) Hardie DG, Hawley A:AMP-activated protein kinase:the energy charge hypothesis revisited. Bio Essays 23:1112-1119, 2001

• 3) Hardie DG, Scott JW Pan DA et al:Management of cellular energy by the AMP-activated protein kinase system. FEB Lett 546:113-120, 2003

P.47 掲載の参考文献

• 1) 佐倉宏:グルコキナーゼとインスリン分泌. 医学のあゆみ 188:301-303, 1999

P.49 掲載の参考文献

• 1) Kawasaki E, Eisenbarth GS:High-throughput radioassays for autoantibodies to recombinant autoantigens. Front Biosci 5:E181-E190, 2000
  pubmed

• 2) Abiru N, Kawasaki E, Eguchi K:Current knowledge of Japanese type 1 diabetic syndrome. Diabetes Metab Res Rev 18:357-366, 2002

• 3) Leslie RD, Atkinson MA, Notkins AL:Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia 42:3-14, 1999
  pubmed

• 4) 川崎英二, 江口勝美:1 型糖尿病の分子マーカー. 医学のあゆみ 207:719-723, 2003
  Medical*Online

P.51 掲載の参考文献

• 1) Kojima M, Hosoda H, Kangawa K:Purification and distribution of ghrelin:the natural endogenous ligand for the growth hormone secretagogue receptor. Horm Res 56 (suppl 1):93-97, 2001

• 2) Nagaya N, Kangawa K:Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept 114:71-77, 2003
  pubmed

P.53 掲載の参考文献

• 1) Ferrara N, Davis-Smyth T:The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997
  pubmed

• 2) Shibuya, M:Vascular Endothelial Growth Factor Receptor-2:its unique signaling and specific ligand VEGF-E (Review). Cancer Science 94:751-756, 2003
  pubmed

• 3) Makinen T, Alitalo K:Molecular mechanisms of lymphangiogenesis (Review). Cold Spring Harb Symp Quant Biol 67:189-196, 2002
  pubmed

P.55 掲載の参考文献

• 1) Rabinovitch A:An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 14:129-151, 1998
  pubmed

• 2) Callard R, George AJ, Stark J:Cytokines, chaos, and complexity. Immunity 11:507-513, 1999
  pubmed

• 3) O'Shea JJ, Ma A, Lipsky P:Cytokines and autoimmunity. Nat Rev Immunol 2:37-45, 2002
  pubmed

P.57 掲載の参考文献

• 1) 南幸太郎, 横倉正明, 清野進:膵β細胞におけるグルコース応答性と細胞内カルシウム. 分子糖尿病学の進歩 2003, 矢崎義雄監修, 金原出版, 東京, 2003, pp.17-22

• 2) Levy J:Abnormal cell calcium homeostasis in type 2 diabetes mellitus:a new look on old disease. Endocrine 10:1-6, 1999
  pubmed

• 3) Levy J, Gavin III JR, Sowers JR:Diabetes mellitus:a disease of abnormal cellular calcium metabolism? Am J Med 96:260-273, 1994

P.59 掲載の参考文献

• 1) Freeman BA, Crapo JD:Biology of disease:free radicals and tissue injury. Lab Invest 47:412-426, 1982
  pubmed

• 2) Sheetz MJ, King GL:Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588, 2002
  pubmed

• 3) Calles-Escandon J, Cipolla M:Diabetes and endothelial dysfunction:a clinical perspective. Endocr Rev 22:36-52, 2001
  pubmed

P.61 掲載の参考文献

• 1) 山田祐一郎:内分泌最近の話題インクレチン. 日本内科学会雑誌 92:72-76, 2003

• 2) 田港朝彦:Glucagon-like peptide-1 (GLP-1) 受容体. 日本臨牀 60 (増刊 7:新時代の糖尿病学 1):535-541, 2002

• 3) Drucker DJ:Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940, 2003
  pubmed

P.63 掲載の参考文献

• 1) 池上博司:HLA 遺伝子-現在まで何がわかったか-. 糖尿病学の進歩 1999 (第33集), 日本糖尿病学会編, 診断と治療社, 東京, 1999, pp.180-186

• 2) 池上博司, 荻原俊男:1型糖尿病遺伝子 (HLA). 糖尿病ナビゲーター, 門脇孝編メディカルレビュー社, 東京, 2002, pp.80-81

• 3) 池上博司:1 型糖尿病の遺伝素因:日本人と欧米人の比較. 糖尿病学 2003, 岡芳知, 谷澤幸生編, 診断と治療社, 東京, 2003, pp.114-124

P.67 掲載の参考文献

• 1) Debnam ES, Unwin RJ:Hyperglycemia and intestinal and renal glucose transport:implications for diabetic renal injury. Kidney Int 50:1101-1109, 1996
  pubmed

• 2) Diez-Sampedro A, Eskandari S, Wright EM et al:Na+-to-sugar stoichiometry of SGLT3. Am J Physiol Renal, Physiol 49:F278-F282, 2001

• 3) Lee WS, Kanai Y, Wells RG et al:The high affinity Na+/glucose cotransporter:re-evaluation of function and distribution of expression. J Biol Chem 269:12032-12039, 1994
  pubmed

• 4) Adachi T, Yasuda K, Okamoto Y et al:T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 49:990-995, 2000
  pubmed

• 5) Arakawa K, Ishihara T, Oku A et al:Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na (+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578-586, 2001
  pubmed

• 6) Isaji M, Fujikura H, Nishimura T et al:Pioneering development of a novel selective inhibitor of low affinity sodium/glucose cotransporter (SGLT2):a new approach to improving diabetes mellitus. FASEB J 15:A214, 2001

• 7) Katsuno K, Fujimori Y Takemura Y et al:KGT-1251, a novel selective SGLT2 inhibitor, has anti-diabetic effect in diabetic rodent models. FASEB J 15:A214, 2001

P.69 掲載の参考文献

• 1) Edlund H:Transcribing pancreas. Diabetes 47:1817-1823, 1998
  pubmed

• 2) Robertson RP, Harmon J, Tran PO et al:Glucose toxicity in beta-cells:type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52 581-587, 2003
  pubmed

• 3) Wilson ME, Scheel D, German MS:Gene expression cascades in pancreatic development. Mech Dev 120:65-80, 2003
  pubmed

P.73 掲載の参考文献

• 1) Rosen ED, Walkey CJ, Puigserver P et al:Transcriptional regulation of adipogenesis. Genes Dev 14:1293-1307, 2000
  pubmed

• 2) 加門淳司, 山内敏正, 門脇孝:PPAR ファミリー (PPARα, PPARδ, PPARγ) . 日本臨牀 60 (増刊 7:新時代の糖尿病学 1):593-600, 2002

• 3) Barbier O, Torra IP, Duguay Y et al:Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726, 2002
  pubmed

P.75 掲載の参考文献

• 1) Barr PJ:Mammalian subtilisins:the long-sought dibasic processing endoproteases. Cell 66:1-3, 1991

• 2) Steiner DF, Smeekens SP, Ohagi S et al:The new enzymology of precursor processing endoproteases. J Biol Chem 267:23435-23438, 1992
  pubmed

• 3) Steiner DF:The proprotein convertases. Curr Opin Chem Biol 2:31-39, 1998
  pubmed

P.77 掲載の参考文献

• 1) Powell SM:15-deoxy-△12,14-PGJ2:endogenous PPARγ ligand or minor eicosanoid degradation product? J Clin Invest 112:828-830, 2003

• 2) Fitzgerald AG:COX-2 and beyond?:Approaches to Prostaglandin Inhibition in Human Disease. Nat Rev Drug Discov 2:879-890, 2003

• 3) Davidge TS:Prostaglandin H synthase and Vascular Function. Circ Res 89:650-660, 2001

P.79 掲載の参考文献

• 1) Nishizuka Y:Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614, 1992
  pubmed

• 2) Nishizuka Y:Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484-496, 1995
  pubmed

• 3) Liscovitch M, Cantley LC:Lipid second messengers. Cell 77:329-334, 1994
  pubmed

• 4) Ishii H, Jirousek MR, Koya D et al:Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272:728-731, 1995

• 5) Koya D, Haneda M, Nakagawa H et al:Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβ inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000

P.81 掲載の参考文献

• 1) Walston J, Silver K, Bogardus C et al:Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 333:343-347, 1995

• 2) Kadowaki H, Yasuda K, Iwamoto K et al:A mutation in the β3-adrenergic receptor gene is a associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 215:555-560, 1995

• 3) Kimura K, Sasaki N, Asano A et al:Mutated human β3-adrenergic receptor (Trp64Arg) lowers the response to β3-adrenergic agonists in transfeOcted 3T3-L1 preadipocytes. Horm Metab Res 32:91-96, 2000

P.83 掲載の参考文献

• 1) Semenkovich CF Heinecke JW:The mystery of diabetes and atherosclerosis. Time for a new plot. Diabetes 46:327-334, 1997
  pubmed

• 2) Beisiegel U, St Clair RW:An emerging understanding of the interactions of plasma lipoproteins with the arterial wall that leads to the development of atherosclerosis. Curr Opin Lipidol 7:265-268, 1996

• 3) Parthasarathy S, Santanam N:Mechanisms of oxidation, antioxidants, and atherosclerosis. Curr Opin Lipidol 5:371-375, 1994
  pubmed

• 4) Itabe H, Yamamoto H, Suzuki M et al:Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 271:33208-33217, 1996
  pubmed

P.85 掲載の参考文献

• 1) Hotta N:New approaches for treatment in diabetes:aldose reductase inhibitors. Biomed Pharmacol 49:232-243, 1995

• 2) Oates PJ, Mylary BL:Aldose reductase inhibitors:therapeutic implications for diabetic complications. Expert Opin Investig Drugs 8:2095-2119, 1999
  pubmed

• 3) 堀田饒:糖尿病性合併症とポリオール経路. Diabetes Frontier 12:13-25, 2001

P.87 掲載の参考文献

• 1) 岡芳知, 後藤雄一:ミトコンドリア糖尿病, 診断と治療社, 東京, 1997

P.89 掲載の参考文献

• 1) Gaw A, Hobbs HH:Molecular genetics of lipoprotein (a):new pieces to the puzzle. Curr Opin Lipidol 5:149-155, 1994

• 2) Klezovitch O, Scanu AM:Heterogeneity of lipoprotein (a):growing complexities. Curr Opin Lipidol 6:223-228, 1995
  pubmed

• 3) Haffher SM:Lipoprotein (a) and diabetes. An update. Diabetes Care 16:835-840, 1993

• 4) 笈田耕治, 中井継彦:トピックスーリポプロテイン (a). Annual Review 内分泌・代謝, 岡博, 永田直一, 金澤康徳,柳沼つとむ編,中外医学社, 東京, 1993, pp.32-36

P.91 掲載の参考文献

• 1) McNamara JR, Shah PK, Nakajima K et al:Remnant like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women:results from the Framingham Heart study. Atherosclerosis 154:229-236, 2001
  pubmed

• 2) Krauss RM:Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 81:13B-17B, 1998
  pubmed

• 3) Jiao S, Matsuzawa Y, Matsubara K et al:Increased activity of intestinal acyl-CoA:cholesterol acyltrasferase in rats with streptozotocin-induced diabetes and restoration by insulin supplementation. Diabetes 37:342-346, 1988

• 4) Kugiyama K, Doi H, Motoyama T et al:Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526, 1998
  pubmed

• 5) 多田紀夫:レムナント様リポ蛋白. 臨床検査 40:1023-1029, 1996

• 6) Kugiyama K, Doi H, Takazoe K et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999
  pubmed

• 7) Ericsson CG:Results of the bezafibrate coronary atherosclerosis intervention trial (BECAIT) and an update on trials now in progress. Eur Heart J 19 (suppl H):H37-H41, 1998

●臨床編

P.95 掲載の参考文献

• 1) 伊藤千賀子:糖尿病の一次予防-疫学研究によるアプローチ, 診断と治療社, 東京, 2000

P.97 掲載の参考文献

• 1) 鹿野昌彦, 傍島裕司:糖尿病における dawn phenomenon. 日本臨牀 55 (増刊:糖尿病 2) 687-694, 1997

• 2) Bolli GB et al:Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 3:71-89, 1993

P.99 掲載の参考文献

• 1) 糖尿病足病変-インターナショナル・コンセンサス, 糖尿病足病変に関する国際ワーキンググループ編, 内村功, 渥美義仁監訳, 医歯薬出版, 東京, 2000, pp.1-97

• 2) American Diabetes Association:Preventive foot care in people with diabetes. Diabetes Care 23 (suppl 1):S55-S56, 2000

• 3) Pinzur MS, Slovenkai MP, Trepman E:Guidelines for diabetic foot care. The Diabetes Committee of the American Orthopaedic Foot and Ankle Society. Foot Ankle Int 20:695-702, 1999
  pubmed

• 4) Jeffcoate W, Macfarlane R:The Diabetic Foot An Illustrated Guide to Management, Chapman and Hall Medical, London, 1995

P.101 掲載の参考文献

• 1) Hotta N, Sakamoto N:Aldose reductase inhibitors. In:The Diabetes Annual, ed. by Alberti KGMM,Krall LP,Elsevier,Amsterdam,1990, pp.330-361

• 2) Tomlinson DR:Aldose reductase inhibitors and the complications of diabetes mellitus. Diabetic Med 10:214-230, 1993
  pubmed

• 3) Yabe-Nishimura C:Aldose reductase in glucose toxicity:a potential target for the prevention of diabetic complications. Pharmaol Rev 50:21-33, 1998
  pubmed

P.103 掲載の参考文献

• 1) 河盛隆造:α-glucosidase 阻害薬. 内分泌・糖尿病科 3:119-124, 1996

• 2) 河盛隆造, 望月健太郎, 田中逸ほか:糖質水解酵素阻害剤の追加療法が SU 剤治療 NIDDM の血糖管理に与える影響糖尿病 39:527-530, 1996

• 3) Chiasson JL, Josse RG, Gomis R et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
  pubmed

• 4) Chiasson JL, Josse RG, Gomis R et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance, the STOP-NIDDM trial. JAMA 290:486-494, 2003
  pubmed

P.105 掲載の参考文献

• 1) Brange J, Owens DR, Kang S et al:Mnomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
  pubmed

• 2) Kang S, Brange J, Burch A et al:Subcutaneous insulin absorption explained by insulin's physicochmical properties. Diabetes Care 14:942-948, 1991
  pubmed

• 3) Howey DC, Bowsher RR, Brunelle RL et al:[Lys (B28), Pro (B29)]-Human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
  pubmed

• 4) Brange J, Volund A:Insulin analogues with improve pharmaco-kinetic profiles. Adv Drug Delivery Rev 35:307-335, 1999

P.107 掲載の参考文献

• 1) Lepore M, Pampanelli S, Fanelli C et al:Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
  pubmed

• 2) 河盛隆造, 岩本安彦, 門脇孝ほか:強化インスリン療法を実施中の 1 型糖尿病患者におけるインスリングラルギンと NPH ヒトインスリンの比較-国内第II/ III相臨床試験-. 臨床医薬 19:423-444, 2003
  Medical*Online

P.109 掲載の参考文献

• 1) 難波光義:インスリンアスパルト (NN-X14) . 日本臨牀 59:2144-2150, 2001
  Medical*Online

• 2) 難波光義:インスリンアスパルト. 日本臨牀 60 (増刊9:新時代の糖尿病学 3):492-497, 2002

• 3) 難波光義, 浜口朋也:超速効型インスリンのメリットとデメリット. プラクティス 19:161-165, 2002
  Medical*Online

• 4) 難波光義, 浜口朋也:新しいインスリン製剤. 成人病と生活習慣病 32:571-578, 2002

• 5) 難波光義, 浜口朋也, 紺屋浩之:日本醫事新報 No.4154:1-8, 2003

P.111 掲載の参考文献

• 1) 岩本安彦, 赤沼安夫:2 型糖尿病患者における二相性インスリンアスパルト-30 のヒトインスリン混合製剤を対照薬とした 48 週間比較試験-国内第III相臨床試験成績-. 臨床医薬 19:891-904, 2003
  Medical*Online

• 2) Christiansen JS, Vaz JA, Metelko Z et al:Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obe Metab 5:446-454, 2003

• 3) Boehm BO, Home PD, Behrendt C et al:Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily:arandomized trial in type 1 and type 2 diabetic patients. Diabetic Med 19:393-399, 2002

• 4) Kvapil M, Mikolajczyk-Swatko A, Ostergaard AH et al:Biphasic insulin aspart 30 combined with metformin provides better glycemic control in poorly controlled type 2 diabetic patients. Diabetes 51 (suppl 2):A104, 2002

• 5) Raz I, Mouritzen U, Vaz J et al:Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy Clin Ther 25:3109-3123, 2003
  pubmed

P.113 掲載の参考文献

• 1) Kawamori R, Morishima T, Ikeda M et al:Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 23:155-161, 1994
  pubmed

• 2) 河盛隆造:インスリン抵抗性の判別. 総合臨牀 45:2722-2726, 1996

P.116 掲載の参考文献

• 1) ACE 阻害薬のすべて-第 3 版-:日和田邦男, 荻原俊男, 猿田享男編, 先端医学社, 東京, 1999

• 2) AII 受容体拮抗薬のすべて-第2版-:荻原俊男, 菊池健次郎, 猿田享男ほか編, 先端医学社, 東京, 2000

• 3) アンジオテンシン II 受容体拮抗薬-第3版-:日和田邦男, 猿田享男, 荻原俊男編, 医薬ジャーナル社, 東京, 2002

P.119 掲載の参考文献

• 1) 川上正舒, 黒木昌寿:アミノグアニジンおよびその他の AGE 阻害薬. 日本臨牀 60 (増刊 9:新時代の糖尿病学 3):601-605, 2002

• 2) Thornalley PJ:Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation end products. Arch Biochem Biophys 419:31-40, 2003
  pubmed

• 3) Vasan S, Foiles P, Founds H:Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 419:89-96, 2003
  pubmed

P.121 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977, 1993

• 2) Rosenzweig JL:Principles of insulin therapy. In:Joslin's Diabetes Mellitus, ed. by Kahn CR, Weir GC, Lea and Febiger, London, 1994, pp.460-488

P.123 掲載の参考文献

• 1) Ito H, Harano Y, Suzuki M et al:Risk factor analyses for macrovascular complication in nonobese NIDDM patients. Diabetse 45 (suppl 3):S19-S23, 1996

• 2) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 3) 川嶋成乃亮:他科から糖尿病専門医に望むもの(4)循環器科. 糖尿病学の進歩 2003, 日本糖尿病学会編, 診断と治療社, 東京, 2003, pp.71-73

P.125 掲載の参考文献

• 1) Ohkubo Y, Kishikawa H, Araki E et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus-a randomized prospective 6-year study-. Diab Res Clin Pract 28:103-117, 1995

• 2) Shichiri M, Kishikawa H, Ohkubo Y et al:Long-term results of the Kumamoto Study on optimal Diabetes control in type 2 diabetic patient. Diabetes Care 23 (suppl 2):B21-B29, 2000

• 3) Wake N, Hisashige A, Katayama T et al:Cost-effectiveness of intensive insulin therapy for type 2 diabetes-A ten-year follow-up of Kumamoto study-. Diab Res Clin Pract 48:201-210, 2000

P.127 掲載の参考文献

• 1) DeFronzo RA, Tobin JD, Andres R:Glucose clamp technique:a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
  pubmed

• 2) Elahi D:In praise of the hyperglycemic clamp. A method for assessment of bet-cell sensitivity and insulin resistance. Diabetes Care 19:278-286, 1996

• 3) Sherwin RS:Evaluation of hypoglycemic counterregulation using a modification of the Andres glucose clamp. Exp Gerontol 28:371-380, 1993
  pubmed

• 4) 丹羽正孝, 河盛隆造:Euglycemic clamp 法および steady state plasma glucose 法. 日本臨牀 60 (増刊 8:新時代の糖尿病学 2) 356-361, 2002

P.129 掲載の参考文献

• 1) Kawamori R, Morishima T, Ikeda M et al:Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 23:155-161, 1994
  pubmed

• 2) Yki-Jarvinen H, Daniels MC, Virkamaki A et al:Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 45:302-307, 1996
  pubmed

• 3) 河盛隆造, 梶本佳孝:glucose toxicity. 1997 糖尿病学, 小坂樹徳, 赤沼安夫編, 診断と治療社, 東京, 1997, pp.139-151

• 4) Kawamori D, Kajimoto Y, Kaneto H et al:Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH (2)-terminal kinase. Diabetes 52:2896-2904, 2003
  pubmed

P.131 掲載の参考文献

• 1) Imagawa A, Hanafusa T, Miyagawa J et al:Anovel sub-type of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301-307, 2000

• 2) Imagawa A, Hanafusa T, Uchigata Y et al:Fulminant type 1 diabetes-A nationwide survey in Japan. Diabetes Care 26:2345-2352, 2003
  pubmed

P.133 掲載の参考文献

• 1) Jaap AJ, Tooke JE:Pathophysiology of microvascular disease in non-insulin-dependent diabetes. Clin Sci 89:3-12, 1995
  pubmed

• 2) 松島雅人, 田嶼尚子:我が国のIDDM疫学の現状と予防. 分子糖尿病学の進歩 1996, 矢崎義雄監修,金原出版, 東京, 1996, pp.165-171

• 3) Donahue RP, Orchard TJ:Diabetes mellitus and macrovascular complications. Diabetes Care 15:1141-1155, 1992
  pubmed

• 4) 松島雅人:糖尿病足病変の疫学. 特集糖尿病足病変. 糖尿病 43:529-530, 2000

P.135 掲載の参考文献

• 1) 渥美義仁, 門脇孝, SCCT グループ:血糖自己測定と SCCT. 分子糖尿病学の進歩-基礎から臨床まで-, 矢崎義雄監修, 金原出版, 東京, 1998, pp.147-150

• 2) 幸野良一, 渡辺雅子, 阿部隆三:糖尿病 (NIDDM) 患者における血糖測定の意義プラクティス 14:395-399, 1997

• 3) 内潟安子:SMBG によるインスリン治療へのフィードバックー責任インスリンという考え方-. 別冊プラクティス SMBG, 日本糖尿病協会編, 医歯薬出版, 東京, 2001

• 4) 清野弘明, 武井泉, 笠井友宏:1 型および2型糖尿病における血糖自己測定の適応, とくにインスリン投与へのフィードバックにおける血糖自己測定の活用と指導患者指導のための SMBG のすべて, 富永真琴編, 日本医学出版, 東京, 2003, pp.19-22

P.137 掲載の参考文献

• 1) 村上英之, 島本和明:インスリン抵抗性. Current Therapy 13:53-58, 1995

• 2) Berne C, Pollare T, Lithell H:Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14 (suppl 4):39-47, 1991

• 3) The National High Blood Pressure Education Program Working Group:National High Blood Pressure Education Program Working Group Report on hypertension in diabetes. Hypertension 23:145-158, 1994

• 4) Brenner BM, Cooper ME, de Zeeuw D et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
  pubmed

P.139 掲載の参考文献

• 1) Austin MA, Edwards KL:Small dense low density lipo proteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 7:167-171, 1996

• 2) Haward BV, Reaven PD, Picard S et al Diabetes and lipids. In:Diabetes and Atherosclerosis, ed. by Drazin B et al, Elsevier Science Publishing, Amsterdam, 1993, pp.3-144

• 3) 動脈硬化性疾患診療ガイドライン 2002 年版. 日本動脈硬化学会, 2002

P.141 掲載の参考文献

• 1) Halter JB:Diabetes Mellitus. In:Principles of Geriatric Medicine and Gerontology, ed. by Hazzard WR, Blass Jp, Halter JB et al, McGRAW-HILL, New York, 2003, pp.855-875

• 2) 横野浩一:高齢者糖尿病診療のポイント. 糖尿病学の進歩 2002, 日本糖尿病学会編, 診断と治療社, 東京, 2002, pp.128-131

P.144 掲載の参考文献

• 1) Sone H, Katagiri A, Ishibashi S et al:Effects of Life-style Modifications on Patients with Type 2 Diabetes:The Japan Diabetes Complications Study (JDCS) Study Design, Baseline Analysis and Three Year-Interim Report. Horm Metab Res 34:509-515, 2002

• 2) Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
  pubmed

• 3) Norris SL, Lau J, Smith SJ et al:Self-management education for adults with type 2 diabetes:a meta-analysis of the effect on glycemic control. Diabetes Care 25:1159-1171, 2002
  pubmed

• 4) Sone H, Ito H, Saito Y et al:The long-term effects of self-management education for patients with type 2 diabetes on glycemic control. Diabetes Care 25:2115-2116, 2002

• 5) 山下英俊:網膜症経過観察プログラムに関する報告書. 厚生科学研究 21 世紀型医療開拓推進研究事業「糖尿病における血管合併症の発症予防と進展抑制に関する研究 (JDCStudy)」平成 14 年度総括・分担研究報告書, 2003, pp.16-33

• 6) 片山茂裕:糖尿病腎症の発症/進展に対するライフスタイル介入の効果に関する報告厚生科学研究 21 世紀型医療開拓推進研究事業「糖尿病における血管合併症の発症予防と進展抑制に関する研究 (JDCStudy)」平成14年度総括・分担研究報告書, 2003, pp.13-15

• 7) 曽根博仁, 赤沼安夫, 山田信博, JDCS グループ:日本人糖尿病患者における動脈硬化性疾患の現状:JDCS より. 糖尿病 46:903-907, 2003

• 8) Sone H, Ito H, Ohashi Y et al:Obesity and type 2 diabetes in Japanese patients. Lancet 361:85, 2003
  pubmed

P.147 掲載の参考文献

• 1) Simpson RW, Shaw JE, Zimmet PZ:The prevention of type 2 diabetes-lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract 59:165-180, 2003
  pubmed

• 2) Tuomilehto J, Lindstrom J:The major diabetes prevention trials. Curr Diab Rep 3:115-122, 2003
  pubmed

P.149 掲載の参考文献

• 1) 難波光義:CSII 治療. 糖尿病 36:1-5, 1993

• 2) 難波光義, 松澤佑次:強化インスリン療法 (CSII とペンシステム) . 治療の最前線 1:354-359, 1994

• 3) 野中共平, 小山研一, 難波光義:CSII. 糖尿病 35 (suppl 2):59-63, 1992

• 4) 難波光義:速効型ヒトインスリン非緩衝液製剤の問題点. 糖尿病 36:501-503, 1993

• 5) 難波光義:CSII 治療 (持続皮下インスリン注入療法) . 妊娠と糖尿病-診療スタンダード, 藤田富雄, 豊田長康編, 金芳堂, 京都, 2002, pp.86-92

• 6) 難波光義, 浜口朋也:CSII の課題と展望. Diabetes Frontier 13:301-311, 2002

• 7) 難波光義, 浜口朋也:CSII の進歩. 糖尿病 45:851-854, 2002

P.151 掲載の参考文献

• 1) Cryer PE, Fisher JN, Shamoon H:Hypoglycemia. Diabetes Care 17:734-755, 1994
  pubmed

P.153 掲載の参考文献

• 1) 武田悼, 並河整, 倉橋明男:小児糖尿病サマーキャンプの現況と今日の問題点. medicina 30:1525-1527, 1993

• 2) 丸山博:IDDM 児のためのサマーキャンプの役割. 小児内科 28:819-822, 1996

• 3) こどもの糖尿病・サマーキャンプのてびき (第3版), 日本糖尿病学会編, 文光堂, 東京, 1997

P.155 掲載の参考文献

• 1) Shichiri M, Kawamori R, Yamasaki Y et al:Wearable-type artificial endocrine pancreas with needle-type glucose sensor. Lancet 2:1129-1131, 1982
  pubmed

• 2) Shichiri M, Sakakida M, Nishida K et al:Enhanced, simplified glucose sensors-long-term clinical application of wearable artificial endocrine pancreas. Artif Organs 22:32-42, 1998
  pubmed

• 3) 福井康裕ほか:特集:体内植え込み型インスリン注入システムの開発動向. 医科器械学 73:389-421, 2003

P.157 掲載の参考文献

• 1) Sutherland, DER:International Pancreas Transplant Registry, 2000

• 2) Number of adult islet allografts in patients with diabetes by year from 1974 through 2000:http://www.med.uni-giessen.de/itr/slides/itr008.jpg

• 3) Shapiro AMJ, Ryan EA, Lakey JR:Clinical islet transplant-state of the art. Transplant Proc 33:3502-3503, 2001

P.159 掲載の参考文献

• 1) Chiasson JL, Josse RG, Gomis R et al:STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002

• 2) Chiasson JL, Josse RG, Gomis R et al:STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003

P.161 掲載の参考文献

• 1) 日本糖尿病学会編:糖尿病治療ガイド 2002〜2003, 文光堂, 東京, 2002, pp.34-38

• 2) 佐倉宏:スルホニル尿素 (SU) 薬. 糖尿病診療マニュアル, 村勢敏郎, 岩本安彦, 春日雅人ほか編 (日本医師会雑誌特別号 10月15日号), 2003, S118-S122

• 3) Kobayashi M, Kaku K, Kawamori R et al:Glimepiride improves HbA1c without weight gain in obese Japanese Type 2 diabetic patients. Diabetes 52 (suppl 1):A97, 2003

P.163 掲載の参考文献

• 1) Kobayashi T, Itoh T, Kosaka K et al:Time Course of Islet Cell Antibodies and B-cell Function in Non-insulin-dependent Stage of Type 1 Diabetes. Diabetes 36:510-517, 1987

• 2) Kobayashi T, Tamemoto K, Nakanishi K et al:Immuno-genetic and clinical characterization of slowly Progressive IDDM. Diabetes Care 16:780-788, 1993

• 3) Nakanishi K, Kobayashi T, Murase T et al:Association of HLA-A24 with complete B-cell destruction in insulin-dependent diabetes mellitus. Diabetes 42:1086-1093, 1993

• 4) 小林哲郎:ゆるやかに進行するインスリン依存型糖尿病 (slowly progressive IDDM). 医学のあゆみ 156:937-941, 1991
  Medical*Online

• 5) Kobayashi T, Tanaka S, Okubo M et al:Unique epitopes of glutamic acid decarboxylase autoantibodies in Slowly Progressive Type 1 Diabetes. J Clin Endcrinol Metab 88:4768-4775, 2003

• 6) Kobayashi T, Nakanishi K, Okubo M et al:GAD anti-bodies seldom disappear in slowly progressive IDDM. Diabetes Care 19:1031, 1996

• 7) Nakanishi K, Kobayashi T, Sugimoto T et al:Predicitive value of insulin autoantibodies for further progression of beta cell dysfunction in non-insulin-dependent diabetics. Diabetes Research 9:105-109, 1988

• 8) Horton V, Stratton I, Bottazzo GF et al:Genetic heterogeneity of autoimmune diabetes:age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43) . UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 42:608-616, 1999
  pubmed

• 9) Kobayashi T, Maruyama T, Shimada A et al:Insulin intervention to preserve β cells in slowly progressive insulin-dependent (Type 1) diabetes mellitus. Ann NY Acad Sci 958:117-130, 2002

• 10) Kobayashi T, Nakanishi K, Sugimoto T et al:Histopathological changes of the pancreas in islet cell antibodies (ICA) positive subjects befre and after the clinical onset of insulin-dependent diabetes mellitus (IDDM). Diabetes 37:24A, 1988

• 11) Nakanishi K, Kobayashi T, Miyashita H et al:Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus. Am J Gastroenterol 89:762-766, 1994
  pubmed

• 12) Shimada A, Imazu Y, Morinaga S et al:T-cell Insulitis found in anti-GAD65+diabetes with residual β-Cell function. Diabetes Care 22:615-617, 1999

• 13) Murao S:Histological changes of the pancreas in an elderly diabetic patient positive for GAD antibody. Intern Med 39:1079-1982, 2000

P.167 掲載の参考文献

• 1) 日本肥満学会, 肥満症診療のてびき編集委員会編:肥満・肥満症の指導マニュアル. 医歯薬出版, 東京, 1997, pp.88-91

• 2) Department of Health and Social Security; Committee on Medical Aspects of Food Policy:The use of very low calorie diets in obesity In:Report on Health and Social Subjects, No 31, Her Majesty's Stationary Office, London, 1987, pp.1-31

P.169 掲載の参考文献

• 1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

• 2) Nathan DM, Lachin J, Cleary P et al:Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348:2294-2303, 2003
  pubmed

P.171 掲載の参考文献

• 1) 石井均:糖尿病患者の QOL. QOL 評価ハンドブック, 池上直巳, 福原俊一, 下妻晃二郎ほか編, 医学書院, 東京, 2001, pp.70-79

• 2) 石井均, Bradley C, Riazi A ほか:糖尿病治療満足度質問表(DTSQ)の日本語訳と評価に関する研究. 医学のあゆみ 192:809-814, 2000

P.173 掲載の参考文献

• 1) Knowler WC, Barrett-Connor E, Fowler SE et al:Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
  pubmed

• 2) Hernan WH, Brandle M, Zhang P et al:Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 26:36-47, 2003

• 3) Diabetes Prevention Program Research Group:Within trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523, 2003
  pubmed

P.175 掲載の参考文献

• 1) Hollander PA, Schwartz SL, Gatlin MR et al:Importance of early insulin secretion-comparison of nateglinide and glyburide in previously diet-treated patient with type 2 diabetes. Diabetes Care 24:983-988, 2001
  pubmed

• 2) 能登谷洋子, 菊池方利:非スルホニル尿素系インスリン分泌促進薬の適応と使用法の実際診断と治療 91:1594-1598, 2003

P.177 掲載の参考文献

• 1) DECODE study group on behalf of the European Epidemiology Study Group:Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001

• 2) Nakagami T; DECODA Study Group:Hyperglycemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47:385-394, 2004

• 3) Chiasson JL, Josse RG, Gomis R et al; STOP-NIDDM Trial Research Group:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM Trial. JAMA 290:486-494, 2003

P.179 掲載の参考文献

• 1) Kobayashi T, Itoh T, Kosaka K et al:Time course of islet cell antibodies and B-cell function in non-insulin-dependent stage of type 1 diabetes. Diabetes 36:510-517, 1987

• 2) Kobayashi T, Tamemoto K, Nakanishi K et al:Immuno-genetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788, 1993

• 3) Kobayashi T, Nakanishi K, Murase T et al:Small doses of subcutaneous insulin as a strategy for preventing slowly progressive. beta-cell failure in islet cell antibody-positive patients With clinical features of NIDDM. Diabetes 45:622-626, 1996
  pubmed

• 4) Kobayashi T, Maruyama T, Shimada A et al:Insulin intervention to preserve βcells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci 958:117-130, 2002

P.181 掲載の参考文献

• 1) Kitzmiller JL, Buchanan TA, Kjos S et al:Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care 19:514-541, 1996

• 2) 健康・栄養情報研究会編:第六次改訂日本人の栄養所要量:食事摂取基準, 第一出版, 東京, 1999

P.185 掲載の参考文献

• 1) EBM に基づく糖尿病診療ガイドライン策定に関する委員会:科学的根拠 (evidence) に基づく糖尿病診療ガイドライン. 糖尿病45 (suppl 1), 1-76, 2002

• 2) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン, 南江堂 東京, 2004

P.187 掲載の参考文献

• 1) O'Hare JA, Abuaisha F, Geoghegan M et al:Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 163:132-135, 1994
  pubmed

• 2) Hinokio Y, Suzuki S, Komatu K et al:A new mitochondrial DNA deletion associated with diabetic amyotrophy, diabetic myoatrophy and diabetic fatty liver. Muscle Nerve 3 (suppl):S142-S149, 1995
  pubmed

• 3) Suzuki Y, Kadowaki H, Atsumi Y et al:A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA (leu;UUR) mutation and successful therapy with coenzyme Q10. Endocr J 42:141-145, 1995
  pubmed

P.189 掲載の参考文献

• 1) Seino Y, Ishida H:Diabetic osteopenia-pathophysiology and clinical aspects. Diabetes Metab Rev 11:21-35, 1995
  pubmed

• 2) 石田均, 鈴木清, 前田圭禧ほか:糖尿病におけるカルシウム代謝異常 (臨床). Clinical Calcium 5:1134-1140, 1995

• 3) 鈴木清, 石田均, 田口吉孝ほか:糖尿病における骨病変. 内分泌・糖尿病科 4:341-347, 1997

• 4) Suzuki K, Sugimoto C, Takizawa M et al:Correlation between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract 48:185-191, 2000
  pubmed

P.191 掲載の参考文献

• 1) Kitabuchi AE, Fisher JN, Murphy MB et al:糖尿病性ケトアシドーシスと高血糖高浸透圧非ケトン状態ジョスリン糖尿病学, 金澤康徳ほか監修:医学書院 MYW, 東京, 1995, pp.725-754

P.193 掲載の参考文献

• 1) 柏木厚典, 西尾喜彦, 紀田康雄:糖尿病と心血管障害. 日本醫事新報 (第3838号):1-7, 1997

• 2) Stern MP:Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44:369-374, 1995
  pubmed

• 3) Lindholm LH, Dahlof B, Edelman JM et al:Effect of losartan on sudden cardiac death in people with diabetes:data from the LIFE study. Lancet 362:619-620, 2003
  pubmed

• 4) Landray MJ, Toescu V, Kendall MJ:The cardioprotective role of beta-blockers in patients with diabetes mellitus. J Clin Pharm Ther 27:233-242, 2002
  pubmed

P.195 掲載の参考文献

• 1) Taylor BV, Dyck PJ:Classification of the Diabetic Neuropathies. In:Diabetic Neuropathy 2nd ed, ed. by Dyck PJ, Thomas PK, W B. Saunder, Philadelphia, 1999, pp.407-414

• 2) Llewelyn JG:The diabetic neuropathies:types, diagnosis and management. J Neurol Neurosurg Psychiatry 74 (suppl 2):ii15-ii19, 2003

P.197 掲載の参考文献

• 1) 糖尿病性腎症病期分類厚生省案の改定について. 糖尿病 44:623, 2001

• 2) Haneda M, Koya D, Isono M et al:Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14:1374-1382, 2003
  pubmed

• 3) Remuzzi G, Schieppati A, Ruggenenti P:Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145-1151, 2002
  pubmed

P.199 掲載の参考文献

• 1) 木村淳, 幸原伸夫:神経伝導検査と筋電図を学ぶ人のために, 医学書院, 東京, 2003

• 2) Kimura J:Electrodiagnosis in diseases of nerve and muscle:principal and practice, F.A. Davis Company, Philadelphia, 1989

• 3) 幸原伸夫, 木村淳:筋電図のすすめ-しびれ, 痛み, 脱力をどのように診断するか-. 医事新報 3577:14-18, 1992

• 4) 幸原伸夫:F 波伝導検査. 臨床検査 40:800-807, 1996

• 5) Dyck PJ, Thomas PK (ed):Peripheral neuropathy, Saunders, NY, 1993

P.201 掲載の参考文献

• 1) Shinozaki K, Suzuki H, Harano Y et al:Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation 92:1749-1757, 1995

• 2) Shinozaki K, Naritomi H, Harano Y et al:Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke 27:37-43, 1996
  pubmed

• 3) Suzuki M, Hattori Y, Takeuchi M et al; MSDM group:Clinical implication of multiple risk factor control in the management of diabetic macrovascular complications. J Diabetes Complications 16:115-118, 2002

• 4) Harano Y, Suzuki M, Koyama Y et al:Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J Diabetes Complications 16:19-23, 2002

P.203 掲載の参考文献

• 1) 伊藤千賀子:糖尿病の診断基準. 糖尿病の管理と予防-疫学研究によるアプローチ-, 診断と治療社, 東京, 2001, pp.22-31

• 2) 日本公衆衛生協会:総合判定. 糖尿病の指導区分に関する検討, 2001, pp.20-21

• 3) 山内俊一・:1,5 アンヒドログルシトール (1,5AG) 日本臨牀 60 (増刊8:新時代の糖尿病学 2):410-414, 2002

P.205 掲載の参考文献

• 1) 葛谷健, 中川昌一, 佐藤譲ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999

• 2) The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
  pubmed

• 3) Report of a WHO Consultation:Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1. Diagnosis and Classification of Diabetes Mellitus. WHO Department of Noncommunicable Disease Surveillance, Geneva, 1999

P.207 掲載の参考文献

• 1) Frank RN:Diabetic retinopathy. N Engl J Med 350:48-58, 2004
  pubmed

• 2) 曽根博仁, 川崎良, 山下英俊ほか:日本の 2 型糖尿病患者における血管合併症とリスクファクター. あたらしい眼科 21:449-453, 2004

• 3) 大黒伸行:糖尿病黄斑症にステロイド局所投与は有効か? あたらしい眼科 20:885-891, 2003
  Medical*Online

P.209 掲載の参考文献

• 1) 北村信一:日本糖尿病療養指導士認定制度の発足と今後の問題点. 糖尿病学 2000, 小坂樹徳編, 診断と治療社, 東京, 2000, pp.199-206

• 2) 北村信一:日本糖尿病療養指導士への期待-認定第1号を迎えて-. 糖尿病の療養指導 2002, 日本糖尿病学会編, 診断と治療社, 東京, 2002, pp.1-5

P.213 掲載の参考文献

• 1) 糸川嘉則, 柴田克己編:栄養学総論, 南江堂, 東京, 1994, p.104

• 2) 山下亀次郎:オリゴ糖と糖質・脂質代謝. Diabetes Frontier 1:51, 1996

• 3) Boyko EJ, Leonetti DL, Bergstrom RW et al:High fasting insulin level and low insulin secretion predict increased visceral adiposity:5 year follow-up among initially non-diabetic Japanese-American men. Submitted. Diabetes Frontier 1:26, 1996

• 4) 豊田隆謙, 猪野康子:糖尿病食事指導の手引き, 南江堂, 東京, 1988, p.17

• 5) 後藤由夫:カルシウムが足りない. 成人病予防のすべて, NHK 出版, 東京, 1995, p.31

• 6) 富田明夫:糖尿病と骨粗鬆症. 骨粗鬆症, 室田景久ほか編, メジカルビュー社, 東京, 1990, p.138

• 7) 後藤由夫:食物繊維の重要性. 成人病予防のすべて, NHK 出版, 東京, 1995, pp.22-23

P.215 掲載の参考文献

• 1) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 2) Kaplan NM:The deadly quartet. Upper-body obesity, glucose intolerance, hyper-triglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989

• 3) DeFronzo RA, Ferrannini E:Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
  pubmed

• 4) Nakamura T, Tokunaga K, Shimomura I et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994

P.217 掲載の参考文献

• 1) Levy J, Atkinson AB, Bell PM et al:Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus:the 10-year follow-up of Belfast Diet Study. Diabet Med 15:290-296, 1998
  pubmed

• 2) 田坂仁正:2 型糖尿病の薬物療法, 経口糖尿病薬, スルホニル尿素薬の構造と作用機序. 日本臨牀 60 (増刊9:新時代の糖尿病学 3):333-338, 2002

• 3) 糖尿病診療ガイドライン, インスリン療法. 糖尿病 45 (suppl 1):31-35, 2002

• 4) Yki-Jarvinen H:Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758-767, 2001
  pubmed

P.219 掲載の参考文献

• 1) 糖尿病診断基準検討委員会:糖尿病の分類と診断基準に関する委員会報告, 糖尿病 42:385-404, 1999

• 2) Metzger BE, Coustan DR, The Organizing Committee:Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 21 (suppl 2):B161-B167, 1998

• 3) 妊婦耐糖能異常の診断と管理に関する検討小委員会:周産期委員会報告 (妊娠糖尿病について), 日産婦誌 47:609-610, 1995

P.221 掲載の参考文献

• 1) Cefalu WT, Skyler JS, Kourides IA et al:Inhaled human insulin treatment in patients with type 2 diabetes melitus. Ann lntera Med 134:203-207, 2001

• 2) Weiss SR, Cheng SL, Kourides IA et al:Inhaled insulin provides improved glycemic control inpatients with type 2 diabetes mellitus inadequately controlled with oral agents. A randomized controlled trial. Arch Inters Med 163:2277-2282, 2003

P.223 掲載の参考文献

• 1) Kirpichnikov D, McFarlane SI, Sowers JR:Metformin:am update. Ann Intern Med 137:25-33, 2002

• 2) Inzucchi SE:Oral antihyperglycemic therapy for type 2 diabetes:scientific review JAMA 287:360-372, 2002
  pubmed

• 3) 藤本新平:ビグアナイド薬の構造と作用機序. 日本臨牀 60 (増刊9:新時代の糖尿病学 3):377-381, 2002

P.225 掲載の参考文献

• 1) 藤島正敏, 篠原規恭, 清原裕ほか:心血管病発症のリスクとしての耐糖能異常-久山町研究-. 糖尿病41 (suppl 2):A45-A47, 1998

• 2) 清原裕:地域住民中の糖尿病者における循環器疾患発症とその危険因子の関連-久山町研究-. 糖尿病合併症 14:80-84, 2000

P.227 掲載の参考文献

• 1) 羽田勝計:糖尿病性腎症の病期腎症前期, 早期腎症. 腎と透析 51 (増刊号):267-271, 2001

• 2) American Diabetes Association:Diabetes nephropathy. Diabetes Care 25:S85-S89, 2002

P.229 掲載の参考文献

• 1) 富永真琴, 大泉英俊:日本の大規模臨床データ(舟形スタディ)から学ぶ. プラクティス 20:173-177, 2003

• 2) 神部裕美, 五十嵐雅彦, 富永真琴:IGT と大血管障害. Diabetes Frontier 14:558-564, 2003
  Medical*Online

P.231 掲載の参考文献

• 1) Suzuki Y, Taniyama M, Muramatsu T et al:Mitochondrial tRNA Leu(UUR) mutation at position 3243 and symptomatic polyneuropathy in type 2 diabetes. Diabetes Care 26:1315-1316, 2003
  pubmed

• 2) Suzuki Y, Suzuki S, Taniyama M et al:Multiple cranial mononeuropathies with acetylcholine receptor antibody in mitochondrial diabetes. Diabetes Care 26:1318, 2003
  pubmed

• 3) Suzuki Y, Iizuka T Kobayashi T et al:Diabetes mellitus associated with the 3243 mitochondrial tRNA(Leu)(UUR) mutation:insulin secretion and sensitivity. Metabolism 46:1019-1023, 1997
  pubmed

• 4) Suzuki Y, Hata T, Miyaoka H et al:Diabetes with the 3243 mitochondrial tRNA Leu(UUR) mutation. Characteristic neuroimaging findings. Diabetes Care 19:739-743, 1996

• 5) Suzuki Y, Tsukuda K, Atsumi Y et al:Clinical picture of a case of diabetes with mitochondrial tRNA mutation at position 3271. Diabetes Care 19:1304-1305, 1996

• 6) Suzuki Y, Suzuki S, Hinokio Y et al:Diabetes associated with a novel 3264 mitochondrial tRNA (Leu) (UUR) mutation. Diabetes Care 20:1138-1140, 1997
  pubmed

P.233 掲載の参考文献

• 1) Rosskamp RH, Park G:Long-acting insulin analogs. Diabetes Care 22 (suppl 2):B109-B113, 1999

• 2) Bolli GB, Perriello G, Fanelli CG et al; Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 16 (suppl 3):71-89, 1993

P.234 掲載の参考文献

• 1) UK Prospective Diabetes Study (UKPDS) Group:Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998

• 2) Stratton IM, Adler AI, Neil HA et al:Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ 321:405-412, 2000

• 3) UK Prospective Diabetes Study (UKPDS) Group:Effects of intensive blood-glucose with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
  pubmed

• 4) UK Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
  Medical*Online
  pubmed

• 5) Adler AI, Stratton IM, Neil HA et al:Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):prospective observational study. BMJ 321:412-419, 2000
  pubmed

• 6) UK Prospective Diabetes Study (UKPDS) Group:Efficacy of athenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317:713-720, 1998

• 7) UK Prospective Diabetes Study (UKPDS) Group:Quality of life in type 2 diabetic patients in affected by complications but not intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22:1125-1136, 1999

• 8) Gray A, Raikou M, McGuire A et al:Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes:economic analysis alongside randomized control trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 320:1373-1378, 2000